Novel diagnostic and prognostic biomarker panel in blood in pancreatic cancer
| Reference number | |
| Coordinator | Lunds universitet - Avdelningen för kirurgi, Inst för kliniska vetenskaper Lund |
| Funding from Vinnova | SEK 1 500 000 |
| Project duration | December 2015 - November 2017 |
| Status | Completed |
Important results from the project
PC lacks methods for early diagnosis and current treatments are ineffective. We aim to develop new biomarkers for PC for early diagnosis and provide a basis for prognosis and therapy. Mass spectrometry (MS) allows for deep sequencing of blood and tissue proteins from patients with PC. Selected biomarkers are verified and validated by targeted MS approaches, incl parallel reaction monitoring (PRM), and antibody-based techniques, e.g. ELISA or immunohistochemistry, in larger cohorts.
Expected long term effects
Serum panels of markers for PC diagnosis with high precision have been defined, verified by ELISA, aiming at screening of risk groups, diagnostics, monitoring, staging and determination of resectability. In about 60,000 PC patients we have shown that even small tumors possess metastatic capability. The role of tumor biology in PC was evaluated by conducting a large MS study on PC tissue. We found a 25 protein marker panel correlating with outcome and a novel histone marker (H1.3) was identified.
Approach and implementation
We have prospectively collected blood and tissues from patients with pancreatic cancer and currently about 300 blood samples and about 100 tissue samples, linked with clinical data in our local biobank is available. Through a national and international collaboration further validation can be performed. Parallel with this, a business development is established using the Lund University Innovation System (Reccan Diagnostics AB).